The latest data point for LLY's Current Contract Liabilities in Q4'25 shows no data, indicating a complete absence of reported values for this period. This follows a pattern of zero liabilities from Q1'24 through Q4'25, with the most recent non-zero figure occurring in Q4'23 at $14.51B USD. Over the period from Q1'23 to Q4'25, the chart reveals a sharp peak in Q4'23 at $14.51B USD, representing a dramatic 634% increase from Q3'23's $1.98B USD, likely due to seasonal revenue recognition or contract timing in the pharmaceutical sector. However, liabilities dropped to zero in Q1'24 and remained there through Q4'25, suggesting potential shifts in deferred revenue obligations, contract completions, or reporting adjustments, with earlier quarters showing modest growth from $0 in Q1'23 to $1.23B USD in Q2'23 before the Q4 surge. This volatile trend highlights instability in short-term contract commitments for LLY.